Renata Jaskula-Sztul Ph.D.

Faculty Member

Selected Publications

Academic Article

Year Title Altmetric
2020 Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumorsCancer Gene Therapy.  27:898-909. 2020
2020 Dual-targeted extracellular vesicles to facilitate combined therapies for neuroendocrine cancer treatment 2020
2020 Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor CellsMolecules.  25. 2020
2020 Cytochrome P4501B1 in bone marrow is co-expressed with key markers of mesenchymal stem cells. BMS2 cell line models PAH disruption of bone marrow niche development functionsToxicology and Applied Pharmacology.  401. 2020
2020 Phosphoprotein-based biomarkers as predictors for cancer therapy 2020
2020 A growth model of neuroendocrine tumor surrogates and the efficacy of a novel somatostatin-receptor–guided antibody-drug conjugate: Perspectives on clinical response?Surgery.  167:197-203. 2020
2020 Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapyCancer Gene Therapy2020
2020 Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance 2020
2020 Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatmentSurgery.  167:189-196. 2020
2020 Targeted Exosomes for Drug Delivery: Biomanufacturing, Surface Tagging, and ValidationBiotechnology Journal.  15. 2020
2019 Pulmonary carcinoid surface receptor modulation using histone deacetylase inhibitorsCancers.  11. 2019
2019 Characterization of somatostatin receptors (SSTRs) expression and antiproliferative effect of somatostatin analogues in aggressive thyroid cancersSurgery.  165:64-68. 2019
2018 Bioprocess development of antibody-drug conjugate production for cancer treatmentPLoS ONE.  13. 2018
2018 Notch3 as a novel therapeutic target in metastatic medullary thyroid cancerSurgery.  163:104-111. 2018
2017 Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1Cancer Medicine.  6:2142-2152. 2017
2017 Notch3 expression correlates with thyroid cancer differentiation, induces apoptosis, and predicts disease prognosisCancer.  123:769-782. 2017
2017 Neuroendocrine Tumor-Targeted Upconversion Nanoparticle-Based Micelles for Simultaneous NIR-Controlled Combination Chemotherapy and Photodynamic Therapy, and Fluorescence Imaging 2017
2017 AB3-loaded and tumor-targeted unimolecular micelles for medullary thyroid cancer treatmentJournal of Materials Chemistry B.  5:151-159. 2017
2017 Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivoOncotarget.  8:70828-70840. 2017
2016 KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapyBiomaterials.  97:22-33. 2016
2016 Notch1 signaling regulates the aggressiveness of differentiated thyroid cancer and inhibits SERPINE1 expressionClinical Cancer Research.  22:3582-3592. 2016
2016 Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapyBiomaterials.  91:1-10. 2016
2015 Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoidsCancer Gene Therapy.  22:496-505. 2015
2015 Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiationCancer Gene Therapy.  22:410-416. 2015
2015 Tumor-suppressor role of notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological inductionMolecular Cancer Therapeutics.  14:499-512. 2015
2014 Hesperetin Activates the Notch1 Signaling Cascade, Causes Apoptosis, and Induces Cellular Differentiation in Anaplastic Thyroid CancerAnnals of Surgical Oncology.  21:497-504. 2014
2014 The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growthJournal of Surgical Research.  190:191-197. 2014
2014 Thiocoraline activates the Notch pathway in carcinoids and reduces tumor progression in vivoCancer Gene Therapy.  21:518-525. 2014
2013 Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapyNanoscale.  5:9924-9933. 2013
2013 Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growthMolecular Cancer Therapeutics.  12:1276-1287. 2013
2013 Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivoCancer.  119:774-781. 2013
2013 Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch 2013
2013 Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell lineCancer Medicine.  2:734-743. 2013
2012 Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapyNanoscale.  4:7185-7193. 2012
2011 Expression of the active notch1 decreases MTC tumor growth in vivoJournal of Surgical Research.  171:23-27. 2011
2011 Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell linesGynecologic Oncology.  122:396-401. 2011
2011 A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma 2011
2011 Identification and validation of Notch pathway activating compounds through a novel high-throughput screening methodCancer.  117:1386-1398. 2011
2010 Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growthMolecular Cancer Therapeutics.  9:429-437. 2010
2008 Suberoyl bishydroxamic acid activates Notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinomaAnnals of Surgical Oncology.  15:2600-2605. 2008
2007 Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cellsJournal of Gastrointestinal Surgery.  11:1515-1520. 2007
2007 Valproic acid activates Notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells 2007
2005 Reduced DNA repair capacity in laryngeal cancer subjects: A comparison of phenotypic and genotypic results 2005
2003 Bone marrow cytotoxicity of benzo[a]pyrene is dependent on CYP1B1 but is diminished by Ah receptor-mediated induction of CYP1A1 in liverToxicology and Applied Pharmacology.  193:84-96. 2003
2001 Association of arylamine N-acetyltransferase (NAT1 and NAT2) genotypes with urinary bladder cancer risk 2001
2000 Polymorphism in detoxifying enzymesPostepy biochemii.  46:50-59. 2000
1999 DNA copy number losses are more frequent in primary larynx tumors with lymph node metastases than in tumors without metastasesCancer Genetics.  114:31-34. 1999
1999 Molecular and cellular alterations in tobacco smoke-associated larynx cancer 1999
1998 Glutathione S-transferase M1 and T1 genotypes and susceptibility to smoking related larynx cancerBiomarkers.  3:149-155. 1998

Education And Training

  • Doctor of Philosophy in Biochemistry, Adam Mickiewicz University/Poznan 1998